-
Peng CHENG
Non-equity Partner / Shanghai
-
Tel +86-21-6061-3498
Email tonypeng@zhonglun.com
-
Practices
Private Equity & Investment Funds, Chinese Mainland Capital Markets, Hong Kong & Overseas Capital Markets
Peng CHENG
Mr. Peng has extensive legal practice experience in both domestic and overseas investment and financing transactions, having represented many well-known US funds and RMB funds, large private enterprises and start-ups in an array of private investment and financing transactions, covering Angel, VC and PE financing rounds and especially Pre-IPO financing rounds aiming at IPO listings in Chinese mainland capital markets. He draws on a depth of experience in domestic capital markets, providing comprehensive professional legal services for his clients.
Mr. Peng has successfully assisted dozens of enterprises to complete their domestic and overseas IPO listings; and in particular, he has considerable expertise in dismantling red-chip structures and assisting his clients to complete their A-share listings in Chinese mainland capital markets.
With his extensive experience in counselling many start-ups in the new economy sector, Mr. Peng is adept in providing tailored, comprehensive, and professional “one-stop” legal services for matters ranging from private equity deals to ESOP, M&A, capital markets, and general corporate legal affairs.
Representative Matters
Private Equity Advised BioTrack Capital on Series B investment in SMT Group Advised BioTrack Capital on Series A investment in Alpmed Advised BioTrack Capital on Series A and B investment in Seeneuro Medical Advised Blue Lake Capital on Series A investment in SENSING Technology Advised Cash Capital on Series A investment in Vision Medicals Advised Ameba Capital on Series A investment in Porotech Advised Ameba Capital on dozens of investments in Coutloot Advised Ameba Capital on dozens of investments in Collov Advised Jushuitan on strategic investments in dozens of projects such as Jishiyu Chat, Dian Plus, and Channelwill Advised Sinopharm Capital and other investors on Series C investment in Sinotau Pharmaceutical Group Advised China Broadband Capital on Series C investment in Persagy Advised Tsinghua Holdings Capital on its investment in a military communication equipment company Advised Double Hundred Fund’s investment in a number of infrastructure projects Advised Morgan Stanley’s RMB fund on its investment in a number of projects in the new economy sector Advised Shenogen Pharma Group on its multiple private equity financing projects Advised Lanhu on its multiple private equity financing projects Advised Waytous on its Series B private equity financing Advised Poweroak on its Series B private equity financing Advised Linkmore on its Series A and A+ private equity financing Advised Meishe SDK on its Series A strategic financing Advised 10K Genomics on its Series A private equity financing Advised Uroaming on its Series A and B private equity financing Capital Markets Advised Dongpeng Ceramics on its A-share IPO on the Shenzhen Stock Exchange ChiNext market Advised an Internet security enterprise on its A-share IPO on the Shanghai Stock Exchange STAR Market Advised GreenTree on its US IPO on the New York Stock Exchange as its underwriter’s legal advisor
-
Bar Admissions/Professional Qualifications
PRC Bar, 2019
-
Education
LL.M., Queen Mary University of London, 2011
LL.B., East China University of Political Science and Law, 2009 -
Professional Experience
Non-equity partner and associate, Zhong Lun Law Firm, 2021 to present
Associate, King & Wood Mallesons, 2014-2021
Associate, King & Capital Law Firm, 2013-2014 -
Languages
Chinese
English